AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04654494 — intervention group
Intervention type: PROCEDURE
Intervention: Total proctocolectomy
Description: excision of the whole large bowel including colon and rectum and end ileostomy fashioning
Study NCT04654494 — intervention group
Intervention type: PROCEDURE
Intervention: Total colectomy
Description: excision of the colon with preservation of the rectum
Study NCT04654494 — intervention group
Intervention type: PROCEDURE
Intervention: Segmental colectomy
Description: excision of a segment of colon
Study NCT01211600 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Staples
Description: Interrupted Ethicon Staples
Study NCT01211600 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Suture
Description: Subcuticular continuous suture (4-0 Monocryl Plus on PS2 needle or 4-0 Vicryl Plus on FS2 or PS2 needle)
Study NCT00779649 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MoviPrep Kit
Description: Diet: At noon the day prior to the procedure, patients will begin a clear liquid diet. Patient will discontinue any ingestion by mouth 4 hours prior to the procedure.~Purgative: Starting at 6pm the evening before the procedure, patient will ingest 250 ml of MoviPrep® at 15 minute intervals until 1 liter is consumed. Following this, an additional 500 ml (approximately 16 oz) of clear liquids will be consumed. The next day, 6 hours before the procedure, the patient will repeat ingestion of one liter MoviPrep® over the course of an hour, again ingesting 250 ml at 15 minute intervals. Patient will then ingest an additional 500 ml (approximately 16 oz) of clear liquid following the MoviPrep® consumption.
Study NCT00779649 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HalfLytely and Bisacodyl Tablets Bowel Prep Kit
Description: Diet: Patients will refrain from solid food and have only clear liquids starting 8 am on the day before colonoscopy. In addition, patients will consume nothing by mouth, except clear liquids, from the time the preparation is completed until midnight. Patients will be instructed not to eat or drink anything from midnight until after the colonoscopy is completed.~Purgative: At noon on the day prior to colonoscopy patients will swallow (not chew or crush) 2 bisacodyl delayed release tablets (10 mg). Once the initial bowel movement has occurred (1 - 6 hours after taking the bisacodyl tablets), or if there has been no bowel movement, not more than 6 hours after ingestion of the bisacodyl tablets patients will then drink the reconstituted HalfLytely® solution over 1 hour and 20 minutes. Patients will drink one 8-oz glass every 10 minutes until the two liters is completed
Study NCT00877812 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Arm 1 glycine and leucine
Description: Arm 1 glycine and leucine: A subset of 14 participants out of the total enrolled participants with an adequate nutritional status will undergo the tracer infusion of glycine and leucine amino acids protocol while an adequate vitamin pyridoxine, B6 status. After the first infusion each participant will then begin a diet low in vitamin B6 (\<0.5 mg/d) for 4 weeks to achieve marginal B6 status followed by a repeat of fasting blood sampling and tracer infusion protocol.
Study NCT00877812 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Arm 2 Intervention of Serine and methionine infusion
Description: Arm 2 Intervention of Serine and methionine infusion: A subset of 14 participants out of the total enrolled participants. Received an adequate nutritional status will undergo the tracer infusion of methionine and serine amino acids protocol while in adequate vitamin pyridoxine, B6 status. After the first infusion each subject will then begin a diet low in vitamin B6 (\<0.5 mg/d) for 4 weeks to achieve marginal B6 status followed by repeat of fasting blood sampling and tracer infusion protocol.
Study NCT00911352 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Frozen gel glove (Elasto-Gel Mitten)
Description: Gel glove is frozen for > 3 hours at -5 to -30°C prior to use. Each patient wears a triple glove set (surgical glove overlaid with cotton glove, overlaid with gel glove) on their intervention hand. Gloves are worn for duration of infusion (15 mins pre, 60 minutes intratreatment and 15 mins post) to ensure the patients' peripheries are vasoconstricted on commencement of the infusion and for enough time afterwards to ensure circulating drug does not reach the target area. Because of the duration of the infusion, more than one gel glove will be used successively (for 45 minutes each) to maintain a consistently low temperature on the hand and nails.
Study NCT02888093 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Absorbent suture (polydioxanone) and Permanent suture (Gore-Tex CV2)
Study NCT03422315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: injection;2mg/kg;single-dose
Study NCT01401725 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic Order Entry System + CDSS
Description: Physicians at this hospital will use an Electronic Order Entry System plus a computerized decision support system (CDSS) to support VTE prophylaxis decisions.
Study NCT01401725 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Order Entry System Only
Description: Physicians at this hospital will use an Electronic Order Entry System
Study NCT01401725 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Physicians at this hospital will practice usual care (no Electronic Order Entry System and no CDSS for VTE prophylaxis decisions)
Study NCT02949180 — intervention group
Intervention type: DEVICE
Intervention: Five minutes puls wave recording
Description: iPhone will be positioned on the index finger for five minutes to record a pulse wave
Study NCT03245073 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Action observation therapy
Description: The normal human movement will be recorded and than the patients will be watched them.
Study NCT03245073 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Strengthening and stretching exercise programme focuses on hip and knee muscles
Study NCT03245073 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Strengthening and stretching exercise programme focuses on hip and knee muscles
Study NCT02529787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxirazole
Description: 1 capsule contains 60 mg Dexlansoprazole
Study NCT02529787 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexilant
Description: 1 capsule contains 60 mg Dexlansoprazole
Study NCT05883891 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: prothrombin time
Description: Prothrombin time at value at diagnosis was used to assess the presence of a correlation with Lille score at day 7 and therefore wether it could predict response to medical treatment.
Study NCT00620412 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus rhamnosus
Description: 2 capsules by mouth 2 times a day for 28 days. Each capsule contains 1x10\^10 LGG organisms.
Study NCT00620412 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo control
Description: 2 capsules by mouth twice a day for 28 days
Study NCT00620412 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Influenza Virus Vaccine Live, Intranasal
Description: intranasal spray, 0.1ml per nostril, one time dose
Study NCT00620412 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza Virus Vaccine Live, Intranasal
Description: intranasal spray, 0.1ml per nostril, one time dose
Study NCT01490437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m2 IV over 10 minutes on D1 every 3 weeks
Study NCT01490437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 70 mg/m2 IV over 60 minutes on D1 every 21 days
Study NCT01490437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 4 mg bid PO from D-1 to D2 every 3 weeks
Study NCT01490437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamins
Description: Folic acid 350 ug - 600 ug daily from D-7 daily vitamin B12 1,000 ug every 9 weeks from D-7
Study NCT02370875 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magstim RapidStim2
Description: Application of repetitious transcranial magnetic stimulation (TMS) pulses using Magstim RapidStim2 to a specific brain target at predefined stimulation parameters.
Study NCT02370875 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Magstim RapidStim2
Description: Same procedure as real rTMS without stimulating the cerebral cortex.
Study NCT03048929 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Typhoid Vi Polysaccharide Vaccine
Description: Salmonella typhi capsular polysaccharide vaccine (Typhoid Vi Polysaccharide Vaccine): Each dose of 0.5ml Salmonella typhi capsular polysaccharide vaccine (Sanofi Pasteur, SA) is formulated to contain 25μg of purified Vi polysaccharide in a colorless isotonic phosphate buffered saline (pH 7±0.3), 4.150mg of sodium chloride, 0.065mg of disodium phosphate, 0.023mg of monosodium phosphate and 0.5ml of sterile water for injection. It is indicated for use by humans aged 2 years and older for protection against typhoid fever.
Study NCT03048929 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo injection will consist of 0.5mL of saline.
Study NCT01173991 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Carbohydrate counting training
Description: Carbohydrate counting was taught during 4-5 individual sessions with a dietician and a diabetologist.
Study NCT01173991 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Carbohydrate counting training
Description: Carbohydrate counting was taught during 4-5 individual sessions with a dietician and a diabetologist.
Study NCT01219010 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Siltuximab
Description: 15mg/kg IV infusion every 3 weeks for 4 cycles. If applicable extended dosing of 15 mg/kg IV infusion every 4 weeks for up to 2 years.
Study NCT02354937 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK1265744 30 mg
Description: White to almost white coated oval tablets with unit dose strength of 30 mg for oral administrations.
Study NCT02354937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744 30 mg
Description: White to almost white coated oval tablets with unit dose strength of 30 mg for oral administrations.
Study NCT04992819 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chronobiological Approach Nutrition Model
Description: In the intervention group, a label containing the time of expressed breastmilk will be affixed. In the milk preparation room, breast milk will be stored in a separate refrigerator as 08:00-19:59 day milk and 20:00-07:59 night milk.
Study NCT01029132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: galantamine
Description: 8 mg/day (4 mg bid) during the first 4 weeks, up to a maximum of 24 mg/day (12 mg bid) at intervals of 4 weeks, from 16 to 24 mg/day based on the patient's tolerability
Study NCT04370080 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silver Diamine Fluoride 38%
Description: Dental caries arrest medication
Study NCT03149081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boswellia
Description: Boswellia is an extract from frankincense
Study NCT02514616 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic IPG and lead implant procedure
Description: EST placement
Study NCT02514616 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Laparoscopic IPG and lead implant procedure
Description: EST placement
Study NCT02514616 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Electric Stimulation Therapy
Description: Device programming by the technician to deliver the EST system active (Treatment group) or no stimulation (Control group) for the following 12 weeks, at the 2 weeks visit.
Study NCT02514616 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Delayed Electric Stimulation Therapy
Description: Device programming by the technician to deliver the EST system no stimulation for the following 12 weeks at the 2 weeks visit. Active Electric Stimulation Therapy will be programmed at the 14 weeks visit.
Study NCT01931657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone prior to Mirena
Study NCT01931657 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo prior to Mirena insertion
Study NCT02103998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thryoid hormone T4 + oral potassium iodide (KI) for 42 days
Description: Continuous infusion of 4 µg/Kg/day T4 with 30 µg/Kg/day oral potassium iodide (KI) for 42 days
Study NCT02103998 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: D5W - 5% dextrose water
Description: Equivalent volume of infusion as study drug
Study NCT03615196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: USB005 (aclerastide) Ophthalmic Solution
Description: Aclerastide (\[Nle3\]-Angiotensin II (1-7)) is aseptically formulated in USB005 Ophthalmic Solution for topical ophthalmic administration. Active pharmaceutical ingredient (API) levels ranging from 0.03% to 0.45% are formulated in a sterile vehicle consisting of 0.06% Sodium Phosphate Monobasic Anhydrous, USP; 3% Glycerol, USP; 1.4% Polyvinyl Alcohol, USP; and 0.5% Hydroxyethylcellulose (HEC 250 HHX), NF in Sterile Water for Injection, USP.
Study NCT02677883 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Symptom-guided thoracentesis
Description: Arm II will undergo a standard of care therapeutic thoracentesis procedure. In this group, the procedure but will be stopped when the patient develops symptoms or when all the fluid has been removed.
Study NCT02677883 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Symptom-guided thoracentesis
Description: Arm II will undergo a standard of care therapeutic thoracentesis procedure. In this group, the procedure but will be stopped when the patient develops symptoms or when all the fluid has been removed.
Study NCT05151276 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mobile phone-based distance video education group
Description: Following the first interview, diabetes education videos created previously were sent to the mobile phones of the individuals in two episodes a week fashion. Video submission was completed in a total of four weeks. In the second interview, three months after the video submission had been completed, data collection forms were re-administered to the individuals, and blood analysis results were recorded.
Study NCT00404469 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: peritendinous corticosteroid injections
Description: 1 ml of40mg/ml methylprednisolone acetate at 0 and 4 weeks. 2 week observational
Study NCT00404469 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: eccentric decline squat training
Description: eccentric decline unilateral squats performed twice daily. for 12 weeks
Study NCT00404469 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: heavy slow resistance training
Description: Heavy slow resistance training for knee extensors. 3/week. total of 12 weeks
Study NCT02797613 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Restricted Reporting
Description: An abbreviated version of the microbiology report indicating that growth is present and the physician should call the lab for further details if clinically important
Study NCT01497223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGCD290
Description: 1 Oral Dose Administration
Study NCT00536419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Methylphenidate SODAS 0.3 mg/kg/day (day 1); 0.7 mg/kg/day (day 2); 1.0 mg/kg/day (days 3 and 4)
Study NCT00536419 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, daily dose, 4 days, oral administration
Study NCT00713518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5 mg ranibizumab
Study NCT00713518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab
Study NCT00713518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 mg PF-04523655
Study NCT00713518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 mg PF-04523655
Study NCT03352609 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active rTMS with MagVenture MagPro double blind rTMS system
Description: 5 sessions of rTMS delivered with MagPro (MagVenture) double blind rTMS system delivered at 110% of resting motor threshold with 3000 pulses of 10hz stimulation (5s on, 10s off) per session.
Study NCT03352609 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: Double blind MagPro system delivers sham condition by mimicking rTMS sound and delivering skin stimulus via TENS pads
Study NCT00530972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a plus ribavirin adjusted to body weight
Description: PegInterferon 180 mcg/week, Adjusted body weight Ribavirin (1000 mg \<75 kg, 1200 mg >75 kg)
Study NCT02506244 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iRhythm ZIO XT Patch
Description: Single-lead ECG monitoring via a wearable patch
Study NCT02506244 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iRhythm ZIO XT Patch
Description: Single-lead ECG monitoring via a wearable patch
Study NCT02506244 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wristband by Amiigo
Description: Determines pulse rate using photoplethysmography.
Study NCT02506244 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wristband by Amiigo
Description: Determines pulse rate using photoplethysmography.
Study NCT00669734 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Falimarev
Description: Given intratumorally or SC
Study NCT00669734 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inalimarev
Description: Given SC
Study NCT00669734 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00669734 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Given SC
Study NCT01673542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine-Prilocaine 5%
Study NCT01673542 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DEXERYL
Study NCT02917122 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active tDCS
Description: Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.
Study NCT02917122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: Patients will take Sertraline.
Study NCT02917122 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sertraline
Description: Patients will take Sertraline.
Study NCT02917122 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham tDCS
Description: Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.
Study NCT01075490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clonidine
Description: addition of 1 µg/kg of clonidine to bupivacaine 1 mg/kg as spinal anesthesia
Study NCT01075490 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: clonidine
Description: equivalent volume of saline added to bupivacaine, 1 mg/kg as spinal anesthesia
Study NCT04053803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMR-687
Description: Oral administration of once daily IMR-687
Study NCT01017302 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutenaous once weekly for 4 weeks
Study NCT01017302 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single subcutaneous dose in week 5
Study NCT01017302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5095932
Description: Escalating subcutaneous doses once weekly over a 4 weeks period
Study NCT01017302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5095932
Description: Single subcutenaous dose in week 5
Study NCT00224640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron chelating intervention
Description: Iron chelating intervention
Study NCT00779350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sertraline 100 mg tablets
Study NCT00779350 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sertraline 100 mg tablets
Study NCT00422682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bsi-201 + topotecan
Description: 21 day cycle
Study NCT00422682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bsi-201 + temozolomide
Description: 28 day cycle
Study NCT00422682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bsi-201 + gemcitabine
Description: 28 day cycle
Study NCT00422682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bsi-201 + carboplatin/paclitaxel
Description: 21 day cycle